Results 171 to 180 of about 4,340 (195)
Some of the next articles are maybe not open access.
A Novel Synthesis and Quantitation Route of Belinostat
Current OrganocatalysisIntroduction: This research article describes the production, quantification, and purification of belinostat from 3-nitrobenzaldehyde as the starting material. A cascade-step process produces higher yields when compared to all previous existing methodologies.
Nagarapu Laxmi Kumari +1 more
openaire +1 more source
Cancer Chemotherapy and Pharmacology, 2015
Belinostat is a potent small molecule inhibitor that exerts its antitumor effect through inhibition of histone deacetylase. The purpose of this study was to evaluate the pharmacokinetics and pharmacodynamics of warfarin (as a reference drug metabolized by CYP2C9) in the presence and absence of belinostat.We conducted a phase I, single-center, open ...
Jordan P Mcpherson +2 more
exaly +3 more sources
Belinostat is a potent small molecule inhibitor that exerts its antitumor effect through inhibition of histone deacetylase. The purpose of this study was to evaluate the pharmacokinetics and pharmacodynamics of warfarin (as a reference drug metabolized by CYP2C9) in the presence and absence of belinostat.We conducted a phase I, single-center, open ...
Jordan P Mcpherson +2 more
exaly +3 more sources
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Journal of Oncology Pharmacy Practice, 2016Peripheral T-cell lymphoma is a heterogenous non-Hodgkin Lymphoma with historically poor outcomes. Currently, response rates remain poor with traditional chemotherapy and many of those responding to initial therapy will relapse. Belinostat (Beleodaq, Spectrum Pharmaceuticals) is a histone deacetylase inhibitor (HDACi) approved for use in relapsed or ...
Peter, Campbell, Christan M, Thomas
openaire +2 more sources
Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia
Acta Haematologica, 2020T-cell large granular lymphocyte (LGL) leukemia is a rare indolent neoplasm primarily treated with immunosuppression. Few therapies and no consensus exist for the optimal treatment of T-cell LGL leukemia refractory to immunosuppressive therapy. Here, we report a case of relapsed/refractory T-cell LGL treated with belinostat.
Christina, Poh +3 more
openaire +2 more sources
Belinostat approved for use in treating rare lymphoma
American Journal of Health-System Pharmacy, 2014FDA on July 3 announced it approved the marketing of belinostat, or Beleodaq, for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Richard Pazdur, head of FDA’s Office of Hematology and Oncology Products, said the drug is the third one that the agency has approved ...
openaire +1 more source
Mechanistic Study of Belinostat Oral Absorption From Spray-Dried Dispersions
Journal of Pharmaceutical Sciences, 2019Spray-dried dispersions (SDDs) are an important technology for enhancing the oral bioavailability of poorly water-soluble drugs. To design an effective oral SDD formulation, the key rate-determining step(s) for oral drug absorption must be understood. This work combined in vivo and in vitro tests with in silico modeling to identify the rate-determining
Aaron, Stewart +8 more
openaire +2 more sources
Molecular Cancer Therapeutics
Abstract The phase III study of romidepsin plus CHOP for peripheral T-cell lymphoma (PTCL) yielded negative results in the overall analysis and showed that outcomes were only improved in the T follicular helper (TFH) subgroup of PTCL, with no benefit in non–TFH PTCL. Belinostat, another histone deacetylase (HDAC) inhibitor, is now the
Jacob C. Pantazis, Adam C. Palmer
openaire +2 more sources
Abstract The phase III study of romidepsin plus CHOP for peripheral T-cell lymphoma (PTCL) yielded negative results in the overall analysis and showed that outcomes were only improved in the T follicular helper (TFH) subgroup of PTCL, with no benefit in non–TFH PTCL. Belinostat, another histone deacetylase (HDAC) inhibitor, is now the
Jacob C. Pantazis, Adam C. Palmer
openaire +2 more sources
Spectrum and TopoTarget in US$350 M Deal for Belinostat
PharmaDeals Review, 2010Spectrum Pharmaceutical is paying US$30 M upfront for TopoTarget’s Phase III lymphoma drug, belinostat, a histone deacetylase (HDAC) inhibitor in development for the treatment of peripheral T cell lymphoma (PTCL). The drug has been granted orphan drug and fast track designation by the FDA.
openaire +1 more source
Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework
Biomedical ChromatographyABSTRACT Belinostat (PXD101), a hydroxamate‐class histone deacetylase inhibitor (HDACi), was approved by the US FDA for patients with relapsed or refractory peripheral T‐cell lymphoma (PTCL). This review covers belinostat's pharmacological characteristics (including its mode of action), pharmacokinetics, toxicity, drug interactions ...
Sanket Chaudhari +4 more
openaire +1 more source